Combat Methamphetamine Epidemic Act of 2005

The Combat Methamphetamine Epidemic Act of 2005 (CMEA) was signed into United States law on March 9, 2006 to regulate, among other things, retail over-the-counter sales of ephedrine, pseudoephedrine, and phenylpropanolamine products. Retail provisions of the CMEA include daily sales limits and 30-day purchase limits, placement of product out of direct customer access, sales logbooks, customer ID verification, employee training, and self-certification of regulated sellers. The CMEA is found as Title VII of the USA PATRIOT Improvement and Reauthorization Act of 2005 (H.R. 3199).^[1] The last provisions of the law took effect on 30 September 2006.

Additional recommended knowledge

Weighing the right way

Essential Laboratory Skills Guide

Safe Weighing Range Ensures Accurate Results

Reason

Ephedrine, pseudoephedrine, and phenylpropanolamine are precursor chemicals used in the illicit manufacture of methamphetamine or amphetamine. They are also common ingredients used to make cough, cold, and allergy products. Passage of the CMEA was accomplished to curtail the clandestine production of methamphetamine. The U.S. Department of Justice claims that states that have enacted similar or more restrictive retail regulations have seen a dramatic drop in small clandestine labs.^[1]

Merchant Restrictions

The Federal statute included the following requirements for merchants who sell these products:

• A retrievable record of all purchases identifying the name and address of each party to be kept for two years.
• Required verification of proof of identity of all purchasers
• Required protection and disclosure methods in the collection of personal information
• Reports to the Attorney General of any suspicious payments or disappearances of the regulated products
• Required training of employees with regard to the requirements of the CMEA; Retailer must self-certify as to training and compliance
• Non-liquid dose form of regulated product may only be sold in unit dose blister packs
• Regulated products are to be sold behind the counter or in a locked cabinet in such a way as to restrict public access
• Daily sales of regulated products not to exceed 3.6 grams without regard to the number of transactions
• 30 day (not monthly) sales limit not to exceed 7.5 grams if sold by mail-order or "mobile retail vendor"
• 30 day PURCHASE limit not to exceed 9 grams of pseudoephedrine base in regulated products (misdemeanor possession offense under 21 USC 844a for the individual who buys it)

First arrest

On March 30, 2007, John P. Gilbride, Special Agent in Charge of the United States Drug Enforcement Administration and United States Attorney Terry Flynn, Western District of New York announced the arrest of William Fousse for violating the Combat Methamphetamine Act by purchasing over 9 grams of ephedrine in a month's time. This investigation revealed that Fousse had purchased 406 Bronkaid caplets which contain 25 mg of ephedrine sulfate per tablet over a two-week period. Further investigation revealed that Fousse had also purchased similar products over the same time period from three other pharmacies. The combined amount of ephedrine purchased was over 29 grams which is over three times what is allowed by law.^[2] Fousse plead guilty to the charges. ^[3]

References

1. ^ ^{a b} The Combat Meth Act of 2005: Assessment of Annual Needs - Questions and Answers. U.S. Department of Justice, Drug Enforcement Administration, Office of Diversion Control (2006-10-18). Retrieved on 2007-04-12.
2. ^ Mulvey, Erin. "First Arrest In The Nation For Violating The Combat Methamphetamine Act" (News Release), U.S. Drug Enforcement Administration, 2007-03-30. Retrieved on 2007-04-12. 
3. ^ Warth, Gary. "Supply-side fight: Loopholes identified in year-old Combat Meth Act" (News), North County Times, 2007-11-24. Retrieved on 2007-12-26.